Pills Scott Barbour/Getty Images

克服新型抗生素的市场障碍

伦敦——如果严格地从某些投资人的角度来看,企业依靠精明的财务管理支撑股价是件好事。按照这种狭隘的逻辑,在涉及医药行业时,我们不必担心推动制药企业股价的不是新发现,而是股票回购或税收倒置等金融策略。

但制药业不同于其他任何产业。它本质上与公共利益息息相关,历史上曾经的医疗创新赋予了人类社会战胜疾病的能力。此外,虽然患者是消费者,但实际的买家往往是政府。即便在美国,公共采购也在处方药市场中也占到至少40%的份额。

产生行业利润的大部分研究同样由政府提供资助。美国政府是全球最大的医疗研发出资人;而在全球范围内,纳税人则承担了1/3的医疗研发开支。因此,决策者坚持将行业创新工作引导到对纳税人和患者最为有利的领域一点不值得大惊小怪,它们不应像金融策略那样在短期内让行业有利可图。

To continue reading, please log in or enter your email address.

To read this article from our archive, please log in or register now. After entering your email, you'll have access to two free articles from our archive every month. For unlimited access to Project Syndicate, subscribe now.

required

By proceeding, you agree to our Terms of Service and Privacy Policy, which describes the personal data we collect and how we use it.

Log in

http://prosyn.org/VMR2UUm/zh;

Cookies and Privacy

We use cookies to improve your experience on our website. To find out more, read our updated cookie policy and privacy policy.